FDA Grants Avastin Safety Hearing For Genentech

Law360, New York (February 24, 2011, 9:15 PM EST) -- The U.S. Food and Drug Administration on Thursday granted Genentech Inc. a hearing to defend its popular drug Avastin as a safe, effective treatment for metastatic breast cancer, after the agency took steps to pull the drug from the market.

The company said the FDA scheduled a hearing for June 28 and 29 to determine whether Avastin should remain approved for use, granting the company’s appeal of the FDA’s December downgrading of the drug.

“We appreciate the opportunity to continue our discussion with the FDA during...
To view the full article, register now.